 | • レポートコード：MRC2303K033 • 出版社/出版日：Mordor Intelligence / 2023年2月 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の調査レポートでは、世界のフィブラート薬剤市場規模が、予測期間中、CAGR 5.2％で増大すると予測されています。本レポートでは、フィブラート薬剤の世界市場を広く調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、薬剤別（クロフィブラート、ゲムフィブロジル、フェノフィブラート、その他）分析、製品種類別（ブランド、一般）分析、流通チャネル別（病院・小売薬局、オンライン薬局）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などについて調査・分析などの項目を掲載しています。並び、こちらのレポートには、Macleods Pharmaceuticals Ltd、Sun Pharmaceutical Industries Ltd、Mylan Inc.、Aurobindo Pharma USA、Sanofi、Zydus Cadila、Lupin、Abbott、Unnati Pharmaceuticals Pvt Ltd、Cipla Inc.、Socosur Chemなどの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界のフィブラート薬剤市場規模：薬剤別 - クロフィブラートの市場規模 - ゲムフィブロジルの市場規模 - フェノフィブラートの市場規模 - その他フィブラート薬剤の市場規模 ・世界のフィブラート薬剤市場規模：製品種類別 - ブランドフィブラート薬剤の市場規模 - 一般フィブラート薬剤の市場規模 ・世界のフィブラート薬剤市場規模：流通チャネル別 - 病院・小売薬局チャネルの市場規模 - オンライン薬局チャネルの市場規模 ・世界のフィブラート薬剤市場規模：地域別 - 北米のフィブラート薬剤市場規模 アメリカのフィブラート薬剤市場規模 カナダのフィブラート薬剤市場規模 メキシコのフィブラート薬剤市場規模 … - ヨーロッパのフィブラート薬剤市場規模 ドイツのフィブラート薬剤市場規模 イギリスのフィブラート薬剤市場規模 フランスのフィブラート薬剤市場規模 … - アジア太平洋のフィブラート薬剤市場規模 中国のフィブラート薬剤市場規模 日本のフィブラート薬剤市場規模 インドのフィブラート薬剤市場規模 … - 南米/中東のフィブラート薬剤市場規模 南アフリカのフィブラート薬剤市場規模 ブラジルのフィブラート薬剤市場規模 アルゼンチンのフィブラート薬剤市場規模 … ・競争状況 ・市場機会・将来動向 |
The fibrate drugs market is projected to register a CAGR of 5.2% during the forecast period.
During the COVID-19 pandemic, the fibrate drugs market was affected due to disruptions in the supply chain. Also, the lack of supply of fibrate drugs during the pandemic increased the demand globally. This rapid increase in demand is due to the increased prevalence of cardiovascular diseases during the COVID-19 pandemic. For example, in 2019, the United States Center for Disease Control and Prevention reported that cardiovascular diseases were prevalent in 9.0% of the patients with COVID-19. According to the study titled “cardiovascular disease and coronavirus disease” published in 2021, physical inactivity due to restrictions may have hampered physical activity prophylaxis effects of cardiovascular diseases. These factors increased the risk of cardiovascular diseases among people, thereby raising the demand for fibrate drugs to treat them, which helps in the market’s growth.
Moreover, the factors such as the rise in the prevalence and increased incidence rate of cardiovascular diseases worldwide are expected to drive the growth of the fibrate drugs market. According to a World Health Organization report, in 2021, an estimated 17.9 million people died from cardiovascular diseases, representing 32% of all global deaths, and of these, 85% were due to heart attacks. The increase in the obese population in developed countries and irregular lifestyles leading to cardiovascular disorders are the key factors for the market’s growth. Also, the vulnerable aging population at elevated risk of developing cardiovascular complications drives the demand for fibrate drugs. According to the study published by the National Institute of Health, in 2020, adults aged 65 and older were more likely than younger people to suffer from cardiovascular disease. Also, in the study “Cardiovascular disease risk factors among older people” published in 2020, the prevalence of cardiovascular disease among older people aged 60-69 years was 72.1% in the United States. Therefore, these factors contribute to the increase in demand for fibrate drugs, which is expected to drive the market’s growth.
Fibrate Drugs Market Trends
Fenofibrate Segment Expected to Hold Major Market Share
During the COVID-19 pandemic, the demand for fibrate drugs increased, resulting in the market’s growth. The fenofibrate segment is expected to hold a majority market share in the forecast period. Various clinical trials have demonstrated that fenofibrate triggers elevated cholesterol and apolipoprotein levels. The observations of fenofibrate in healthy volunteers resulted in steady-state maintenance of cholesterol and fatty acids for 6-8 months. According to the study on the effects of fenofibrate treatment on cardiovascular diseases published in 2019, fenofibrate significantly reduced cardiovascular disease events in those with low HDL cholesterol or hypertension. Also, it helped in 27% of the cardiovascular disease risk reduction. The clinical trials proved that fenofibrate decreases the plasma levels of lipoproteins by 7% to 23%. It also reduces fibrinogen and lowers the levels of serum uric acid. Therefore, the increase in demand for the fenofibrate drug due to its safety and efficacy is expected to fuel the market’s growth in this segment.
North America Expected to Hold Significant Market Share and Expected to do the Same in the Forecast Period
North America is expected to hold a major market share in the global fibrate drugs market due to the high prevalence of the cardiovascular population and rapidly aging population. According to the Center for Disease Control and Prevention, in 2021, about one person died every 36 seconds in the United States from cardiovascular disease. Therefore, the increasing prevalence of cardiovascular disease resulted in the increasing demand for fibrate drugs to treat them effectively. As per the same source, about 659,000 deaths occurred due to heart diseases. This is due to the unhealthy cholesterol buildup in the heart’s coronary artery, which fibrate drugs can effectively treat. Therefore, the growth of the fibrate drugs market is comparatively high in the United States to prevent the increasing incidences of cardiovascular diseases among the population.
Moreover, an increase in R&D activities and the presence of favorable healthcare infrastructure are fueling the growth of the overall regional market to a significant extent.
Fibrate Drugs Market Competitor Analysis
The Fibrate Drugs market is fragmented competitive and consists of several major players. In terms of market share, a few major players are currently dominating the market. Some of the companies currently dominating the market include MacleodsPharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma USA, Sanofi, Zydus Cadila, Lupin, Abbott, Unnati Pharmaceuticals Ltd, Mylan Inc., Cipla Inc., and Socosurchem.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in the Burden of Cardiovascular Diseases Cases
4.2.2 High Investment in the Research and Development of Drugs
4.3 Market Restraints
4.3.1 Frequent Product Recalls/Discontinuation
4.3.2 Stringent Regulatory Framework
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Drug
5.1.1 Clofibrate
5.1.2 Gemfibrozil
5.1.3 Fenofibrate
5.1.4 Other Drugs
5.2 By Product type
5.2.1 Branded
5.2.2 Generic
5.3 By Distribution channel
5.3.1 Hospital and Retail Pharmacy
5.3.2 Online pharmacy
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 COMPANY PROFILES
6.1.1 Macleods Pharmaceuticals Ltd
6.1.2 Sun Pharmaceutical Industries Ltd
6.1.3 Mylan Inc.
6.1.4 Aurobindo Pharma USA
6.1.5 Sanofi
6.1.6 Zydus Cadila
6.1.7 Lupin
6.1.8 Abbott
6.1.9 Unnati Pharmaceuticals Pvt Ltd
6.1.10 Cipla Inc.
6.1.11 Socosur Chem
7 MARKET OPPORTUNITIES AND FUTURE TRENDS